Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Mark A. Socinski, Tony S. Mok, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodriguez-Abreu, Denis Moro-Sibilot, Christian A. Thomas, Fabrice Barlesi, Gene Finley, Shengchun Kong, Xiaoyan Liu, Anthony Lee, Shelley Coleman, Geetha Shankar, Martin Reck
Institutions: AdventHealth Orlando, State Key Laboratory of Oncology in South China, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Rocky Mountain Cancer Centers, Instituto Nacional del Tórax, Moscow City Oncology Hospital №62, Shikoku Cancer Center, Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Centre Hospitalier Universitaire de Grenoble, New England Cancer Specialists, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Allegheny Health Network, Annexon Biosciences (United States), Instacart (United States), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3083101654